cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Mustofa
Contact Email
mustofafk@ugm.ac.id
Phone
+6281328749273
Journal Mail Official
mustofafk@ugm.ac.id
Editorial Address
Department of Pharmacology and Therapy Radioputro Building 2nd Floor Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada Jl. Farmako Sekip Utara, Yogyakarta 55281 Indonesia
Location
Kab. sleman,
Daerah istimewa yogyakarta
INDONESIA
Indonesian Journal of Pharmacology and Therapy
Published by Universitas Gadjah Mada
ISSN : -     EISSN : 2745455X     DOI : https://doi.org/10.22146/ijpther.10147
Core Subject : Health, Science,
Immunology & microbiology Medicine & Pharmacology
Indonesian Journal of Pharmacology and Therapy (IJPTher ) is a scientific journal which published by Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI). IJPTher is an open-access, and double-blind peer-reviewed journal published three Issues a year. IJPTher aims to communicate high-quality articles in the fields of pharmacology. IJPTher publishes original articles, review articles, case reports and book reviews in the fields of pharmacology including basic pharmacology, clinical pharmacology, pharmacotherapy, pharmacoepidemiology, pharmacogenetics, pharmacogenomics, pharmacoeconomic, toxicology and toxicogenomics.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 3 Documents
 1 
Search results for , issue "Vol 7 No 1 (2026)" : 3 Documents clear
Network pharmacology approach to identifying optimal therapeutic targets in cancer drug discovery and development: Bibliometric analysis and scoping review Rovik, Anwar; Henra, Henra; Rahman, Farras Alifia; Afkarina, Izza; Conara, Flafiani Cios
Indonesian Journal of Pharmacology and Therapy Vol 7 No 1 (2026)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.13076

Abstract

A rise in chronic diseases, including cancer, increasingly strains public health. While conventional drug discovery often focuses on single molecules, this method frequently fails to address complex diseases with multiple causes. Network pharmacology, a systems biology approach, provides a more complete understanding of disease mechanisms by analyzing intricate biological networks. By combining multi-omics data and computational models, network pharmacology helps identify new drug targets and cellular pathways. This approach is especially promising in cancer research, where it can reveal complex interactions between genes, proteins, and metabolites. This review explains the principles of network pharmacology and its use in cancer drug discovery. We cover the process, from network building and analysis to experimental testing. Additionally, we examine how network pharmacology can speed up the development of personalized cancer treatments.
Navigating bioethical frontiers: critical concerns in biobanking Salma Darmayanti; Nuke Ayu Febryana; Zafrullah, Adila; Novian Wildan Rosyidi; Isna Maulida Hanum; Dellarious Benefit Yubaidi
Indonesian Journal of Pharmacology and Therapy Vol 7 No 1 (2026)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.13307

Abstract

A biobank constitutes a systematically organized collection of biological specimens, accompanied by corresponding data and information. These specimens encompass a range of materials such as genetic matter (RNA, DNA, cDNA), blood, serum, plasma, urine, tissue and others. Particularly valuable in longitudinal cohort studies, biobanks facilitate the accumulation of samples over extended durations. This is made feasible by the storage facilities within biobanks, which ensure the preservation of specimen quality over time. However, the utility of biobanks across diverse domains brings to the fore a spectrum of ethical dilemmas, encompassing aspects like informed consent, confidentiality, ownership, property rights, commercialization, feedback mechanisms, and re-contact procedures. Informed consent stands as a cornerstone in a biobank operation. Studies indicate a preference for broad consent due to the forward-looking nature of biobank research and its alignment with prevailing ethical standards. Concurrently, the establishment of a tailored regulatory framework becomes imperative to uphold robust ethical oversight, while also accommodating the values of participants. Addressing concerns regarding ownership, property rights, and commercialization entails the formulation of comprehensive agreement forms detailing donor identity, sample type, intended usage, and potential commercial prospects. Furthermore, ensuring adherence to data confidentiality and individual privacy mandates equips researchers and biobank personnel with ethics training. Regular monitoring and evaluation serve to verify compliance with confidentiality regulations. In instances of noteworthy findings, the biobank can provide feedback or initiate re-contact, with protocol adjustments made in alignment with ethical principles. Consideration may also be given to re-consent procedures as deemed necessary. These protocols may be integrated into the original informed consent documentation, with oversight responsibilities vested in the ethics committee of each biobank.
Correlation between mean arterial pressure (MAP) and length of stay (LoS) of heart failure in-patients with sacubitril/valsartan and ramipril at X Hospital Semarang Hadianti Deliana R; N Setiawati, Maria Caecilia; Fef Rukminingsih
Indonesian Journal of Pharmacology and Therapy Vol 7 No 1 (2026)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.26456

Abstract

Heart failure is a health problem with high morbidity and mortality rates globally and nationally, so optimal therapy is needed to improve clinical outcomes and efficiency. Sacubitril/valsartan (angiotensin receptor neprilysin inhibitor/ARNI) and ramipril (ACE inhibitor/ACEi) have become the therapeutic options in heartfailure patients. However, the effectiveness of both therapies on length of stay (LoS) and changes in mean arterial pressure (MAP) in the Indonesian population has not much studied. This study used an observational retrospective design on the medical record data of heart failure inpatients at X Hospital, Semarang,during January to December 2024 period. All in-patients who received sacubitril/valsartan or ramipril therapy (in combination with beta blockers and aldosterone receptor antagonists) were included, and were differentiated based on changes in MAP (up, down and constant). Correlation statistical analysis was performedwith normality test, Kruskal-Wallis, and Anova tests to correlate the LoS and MAP changes between therapy. A total of 131 patients were categorized by therapy and MAP changes. The average LoS on Sacubitril/valsartan and Ramipril therapy was approximately 5–6 d each for the entire MAP change group. Statistical testsshowed no significant difference between the two therapies for LOS, as well as of MAP changes (p > 0.05). MAP changes (up, down, constant) in heart failure in-patients treated with sacubitril/valsartan and ramipril provided variation in LoS, but the differences were not statistically significant between the two therapies.

Page 1 of 1 | Total Record : 3

 1 

Filter by Year

2026 2026


Reset
Filter By Issues
All Issue Vol 7 No 1 (2026) Vol 6 No 3 (2025) Vol 6 No 2 (2025) Vol 6 No 1 (2025) Vol 5 No 3 (2024) Vol 5 No 2 (2024) Vol 5 No 1 (2024) Vol 4 No 3 (2023) Vol 4 No 2 (2023) Vol 4 No 1 (2023) Vol 3 No 3 (2022) Vol 3 No 2 (2022) Vol 3 No 1 (2022) Vol 2 No 3 (2021): Special Issue: COVID-19 Vol 2 No 3 (2021) Vol 2 No 2 (2021) Vol 2 No 1 (2021) Vol 1 No 2 (2020) Vol 1 No 1 (2020) More Issue